The US FDA has now formally joined the growing chorus of concern about whether the Generating Antibiotics Incentives Now (GAIN) Act has been fulfilling its intended goal of incentivizing antibacterial drug development.
In a five-year progress report to Congress required by the GAIN Act, a series of provisions of the 2012...







